MANCHESTER, Conn., Dec. 20, 2010 (GLOBE NEWSWIRE) -- Charter Medical, a subsidiary of Lydall, Inc. (NYSE:LDL) announced today that it has received 510(k) clearance on its next generation Cell Freeze ® Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC's). The issuance of the clearance by the U.S. Food and Drug Administration (FDA) allows Charter Medical to begin marketing the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC's. This next generation of containers offers a broader size range from 50 mL to 750 mL, redesigned configuration for easier use, and the same unique film as its predecessor product. Joe Petrosky, Vice President of Global Marketing and Sales for Charter Medical, stated, "We are excited with this new product as it completes our freezing container platform which serves several high growth markets spanning from medical to cellular therapy and to bio / pharma processing." Dale Barnhart, CEO of Lydall, stated, "I am pleased with the rapid deployment of this new product which was designed side by side with our customers. It demonstrates our commitment to being the supplier of choice as we grow our presence in these important life sciences markets." About Lydall, Inc. Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, the Netherlands and Germany and sales offices in the U.S., Europe, and Asia, manufactures specialty engineered products for the thermal/acoustical and filtration/separation markets. For more information, visit http://www.lydall.com. Lydall ® is a registered trademark of Lydall, Inc. in the U.S. and other countries. All product names are trademarks of Lydall, Inc. or Charter Medical, Ltd.
CONTACT: Charter Medical Peggy Niston, Global Product Manager (336) 768-6447 Fax: (336) 774-1750 email@example.com www.chartermedical.com 3948-A Westpoint Blvd Winston-Salem, NC 27103 Lydall, Inc. Peter M. Kurto, Vice President Business Development & Investor Relations 860-646-1233 Fax: 860-646-4917 firstname.lastname@example.org www.lydall.com